ArticleThrombosis journal2015

Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.

Luke Bamber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.